TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:~  1. Acute presentation within 1 week of a known clinical insult or new/ worsening respiratory symptoms~ 2. Bilateral opacities on chest imaging - not fully explained by effusions, lobar/lung collapse, or nodules~ 3. Respiratory failure is not fully explained by cardiac failure or fluid overload (Echocardiographic assessment to exclude hydrostatic edema)~ 4. Impaired oxygenation with PaO2/ FiO2 ratio less than 300 or Oxygenation Index greater than 5.3~Exclusion Criteria:~* Greater than 24 hours since diagnosis of ARDS~* Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing)~* Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema~* Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease~* Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria)~* Symptomatic or uncorrected congenital heart disease or a right to left intra-cardiac shunt~* Any underlying condition that is likely to impair spontaneous respiratory drive/ efforts (Eg: Brainstem dysfunction, neuromuscular paralysis)~* Underlying chronic diseases (Eg: Cystic fibrosis, Chronic lung disease, etc)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Airway pressure release ventilation arm (Type: EXPERIMENTAL): This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups.
- Low-tidal volume ventilation arm (Type: ACTIVE_COMPARATOR): Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inpatient in NICU at UUMC, PCMC, or IMC~* Gestational age at birth ≤ 32 weeks~* Birth weight ≤ 1500 grams~* Age ≤ 12 weeks of life~Exclusion Criteria:~* Lack of parental consent~* Multiple congenital anomalies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- Infants requiring PRBCs (Type: None): Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Root Cause Determination of Catheter Obstructions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- collection (Type: OTHER): collection of biological and device samples

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed metastatic (stage IV) colorectal cancer~* Undergoing chemotherapy (have had 1 or 2 chemotherapy cycles infused at time of data collection; this will allow for any systemic inflammatory changes due to chemotherapy to set in); only patients with 1st or 2nd line therapy will be included~* Able to initiate a supervised exercise program (free from any CV, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity)~* Free from uncontrolled chronic disease including diabetes, hypertension, or thyroid disease~* Currently participate in less than 60 minutes of physical activity/week~* Willing to travel to the exercise facility at University of Southern California (USC) (parking fees and public transportation permits will be provided)~* Speak English or Spanish~Exclusion Criteria:~* Uncontrolled hypertension or other uncontrolled chronic disease (e.g. diabetes mellitus, thyroid disease, pulmonary disease, etc)~* Moderate to highly active level of physical activity (e.g. currently participating in \> 60 minutes of moderate aerobic activity weekly)~* Orthopedic or other restrictions or contraindications to exercise~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive Care (aerobic exercise) (Type: EXPERIMENTAL): Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Supplements for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (≥18) who test positive for SARS-CoV-2 in an outpatient setting~2. Access to internet~Exclusion Criteria:~1. Symptom onset greater than 4 days prior to enrolment~2. Supplementing regularly with \>500 mg vitamin C, \>1000 units vitamin D, \>120 mcg vitamin K (any form), or \>15 mg zinc taken daily within the past month~3. Currently taking warfarin or an equivalent vitamin K antagonist anticoagulant~4. End stage chronic kidney disease~5. History of calcium oxalate kidney stones~6. Active granulomatosis (sarcoidosis, tuberculosis, lymphoma)~7. Known hypercalcemia or hypervitaminosis D~8. Currently taking either of the following antibiotics: cephalexin, tetracyclines~9. Participating in an investigational study or participation in an investigational study within the past 30 days~10. Any reason which, under the discretion of the qualified investigator or delegate, would preclude the patient from participating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Specific Product: Vitamin D3 50,000 IU~Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period~Specific Product: Vitamin K2/D~Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).~Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.~Specific Product: Vitamin C/Zinc~Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day.
- Control (Type: PLACEBO_COMPARATOR): Specific Product: Vitamin D3 50,000 IU~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg~Specific Product: Vitamin K2/D~Placebo Equivalent: Medium chain triglyceride oil~Specific Product: Vitamin C/Zinc~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Study for Evaluate of Satety and Dfficacy of Hemostatic Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged over 20 years~* Underwent coronary angiography under suspicion of coronary artery disease~* Agreed to participate in the trial before the coronary angiography procedure~Exclusion Criteria:~* Bleeding tendency due to congenital or acquired disorders such as severe liver disease, thrombocytopenia (platelet count below 50,000 cells/μL)~* Those who were on anticoagulants.~* Patients who could not provide voluntary consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- TRAcelet™ compression group (Type: EXPERIMENTAL): the group using TRAcelet™ received 2 hours and 15 minutes of compression from the device with 13 cc of air being blown in, followed by 3 stepwise releases every 15 minutes through counterclockwise rotation of the dial without extracting air using a syringe. This achieved the same 3 hours of compression. The dial started at the triangle position and was set to nine, six, and three at every stepwise decompression. After three hours, the device was released.
- Conventional compression group (Type: OTHER): Patients who were assigned to the conventional group received radial artery compression by a gauze pad folded into a cuboid shape, fastened with 3M™ Durapore™ surgical tape. The gauze pad was not impregnated with prothrombotic material. Compression was released at 3 hours to check for complications. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of study 6002-INT-001~* Not of childbearing potential~Exclusion Criteria:~* Cancer within 5 years of enrollment~* ALT/AST levels \> 2.5 times ULN

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed Parkinson´s Disease with Hoehn Yahr scale between 2,5 and 4,0~* Main complaint of balance or freezing of gait~* Score of 2 or more on subitem 3.11 of the MDS UPDRS scale concerning Freezing of Gait severity.~* Capable of informed consent~Exclusion Criteria:~* Frequent lower limb, lower back or hip pain scoring 3 or more on visual analog scale~* Uncontrolled or serious comorbidities such as uncontrolled diabetes mellitus, renal disease, anticoagulation, immunosuppression or other medical conditions that present a contraindication for SCS surgery~* Psychosis, uncontrolled depression (BDI \>14) or anxiety disorder (BAI \>14)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active stimulation (Type: EXPERIMENTAL): During active stimulation phase, patients will receive through the spinal cord stimulator active tonic stimulation with amplitude set to 90% of paresthesia inducing threshold, therefore allowing blinding. Patients will be evaluated after a three week wash out period with no stimulation and after three weeks of continuous active stimulation.
- Sham stimulation (Type: SHAM_COMPARATOR): During sham stimulation phase, patients will receive through the spinal cord stimulator a zero amplitude stimulation, therefore having no electrical current passing through epidural leads but with the program status still displayed as on if checked with patient's personal controller. Patients will be evaluated after a three week wash out period with no stimulation and after three weeks of continuous sham stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemically Assisted Capsulectomy-A New Clinical Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All females undergoing capsulectomy~Exclusion Criteria:~* All pregnant women and nursing mothers will be exclued

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard treatment (Type: NO_INTERVENTION): Standard treatment
- Use of Mesna (Type: EXPERIMENTAL): Standard surgical procedure with Mesna

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe non-proliferative diabetic retinopathy or retinal neovascularization secondary to diabetic retinopathy meeting DRS criteria for PRP laser~* ETDRS (Early treatment of Diabetic Retinopathy Study) eye score of at least 34-73 letters (at 2 meters) (20/20 to 20/320) for study eye and 20/800 in non-study eye~* Clinical evidence of macular microantiopathy in the study eye (lipid or retinal thickness is acceptable)~* No other ocular disease that could be responsible for decreased vision, macular edema or could limit macular imaging~Exclusion Criteria:~* Individuals with retinal neovascularization from causes other than diabetic retinopathy~* Any intraocular surgery within 2 months or Yag capsulotomy within 1 month in the study eye~* Prior retinal or vitreous surgery (including posterior segment vitrectomy or scleral buckling)~* Medical conditions requiring the use of mineral supplements (copper in particular)~* Individuals with anemia~* Individuals with mental or physical disabilities that prevent accurate vision testing~* History of treatment of PDR by PRP~* Active hepatitis, clinically significant liver disease or any evidence of renal failure.~* Stroke or myocardial infarction within preceding 6 months or ventricular tachycardia under treatment~* History of severe cardiac disease or unstable angina~* Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks~* Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections~* Women of childbearing potential not on 2 effective forms of birth control~* Women who are pregnant or plan to become pregnant~* Subjects with an allergy to fluorescein dye.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm II (Type: EXPERIMENTAL): None
- Arm I. Placebo + Pan-Retinal Photocoagulation (Type: PLACEBO_COMPARATOR): All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of High Dose Vitamin D in Patient's With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CD~* Age \>= 18 and \<75~* Vitamin D deficiency or insufficiency (serum 25-hydroxyvitamin D \< 30ng/ml)~Exclusion Criteria:~* Corticosteroid use in the last 4 weeks~* CD-related surgery in the last 6 months~* CD-related hospitalization in the last 4 weeks~* Pregnancy, intended pregnancy during the study period or nursing~* Serum calcium \>10.2 mg/dL~* History of primary sclerosing cholangitis~* History of undergoing an ileal pouch-anal anastomosis~* Current active perianal disease~* History of nephrolithiasis in the past 2 years~* Anticipated change in therapy in the next 30 days (steroids, biologic initiation)~* modified Harvey-Bradshaw Index of 10 or more~* History of decreased renal function (glomerular filtration rate \<30ml/min based on MDRD) or polycystic kidney disease~* History of sarcoidosis~* History of hyperparathyroidism~* Any other chronic condition that may preclude high doses of Vitamin D such as lymphoma~* Concurrent use of hydrochlorothiazide, phenytoin, phenobarbital, carbamazepine or primidone~* Osteoporosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Vitamin D (Type: ACTIVE_COMPARATOR): Patients will be given 400 IU cholecalciferol once daily for 30 days. \<-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
- High Dose Vitamin D (Type: EXPERIMENTAL): Patients will be given cholecalciferol 10,000 IU daily for 30 days. \<-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if \<50 ng/ml, a 30 day course will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* low back pain for 3 months or longer, confirmed by radiographic evidence.~* receiving a stable dose of an opioid analgesic for low back pain.~Exclusion Criteria:~* taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.~* requiring frequent analgesic therapy for chronic condition(s), in addition to low back pain.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS 5 (Type: ACTIVE_COMPARATOR): Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
- Oxycodone Immediate-Release (Type: EXPERIMENTAL): Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obstetrics and gynecology or general surgery residents in ACGME accredited programs naïve to robotic surgery training~* Completion of the online orientation to daVinci Surgical System~Exclusion Criteria:~* Performance of any robotic surgical procedures as the console surgeon~* Performance of any robotic simulator protocols~* Any significant amount of time spent on a virtual reality robotic simulator

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mimic dV-Trainer (Type: OTHER): None
- daVinci Skills Simulator (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues